Claims for Patent: 7,642,234

Summary for Patent: 7,642,234

Title:	Beta-2-glycoprotein 1 is an inhibitor of angiogenesis
Abstract:	The present disclosure provides a method of inhibiting angiogenesis within a tissue of interest by providing either intact or nicked .beta.-Glycoprotein 1 (.beta.2GP1) to cells associated with the tissue. The presence of .beta.2GP1 inhibits angiogenesis within the tissue, in part by preventing neovascularization into the tissue. The disclosure also provides a method for treating tumors by providing .beta.2GP1 to the tumor.
Inventor(s):	Schroit; Alan Jay (Bellaire, TX), Balasubramanian; Krishnakumar (Pearland, TX), McCarty; Marya F. (Bellaire, TX)
Assignee:	Board of Regents The University of Texas Systems (Austin, TX)
Application Number:	11/810,521
Patent Claims:	1. A method of inhibiting angiogenesis and/or angioectasia at a site in a subject suffering from an angiogenic disease of the eye, skin, joints, gastrointestinal tract, reproductive system, or involved with fracture or wound healing, comprising administering an effective amount of N-.beta.2GP1 to the subject, wherein the amount is sufficient to inhibit angiogenesis and/or angioectasia at the site. 2. The method of claim 1, wherein angiogenesis is inhibited at the site. 3. The method of claim 1, wherein angioectasia is inhibited at the site. 4. The method of claim 1, wherein the N-.beta.2GP1 is administered to the subject orally, intravenously, subcutaneously, intramuscularly, or topically. 5. The method of claim 1, wherein the angiogenic disease is characterized by persistent unregulated angiogenesis. 6. The method of claim 1, wherein the angiogenic disease is an angiogenic disease of the eye. 7. The method of claim 1, wherein the site is dermis, epidermis, endometrium, retina, surgical wound, gastrointestinal tract, umbilical cord, liver, kidney, reproductive system, lymphoid system, central nervous system, breast tissue, urinary tract, bone, muscle, or respiratory tract. 8. The method of claim 1, wherein the N-.beta.2GP1 is substantially pure N-.beta.2GP1. 9. The method of claim 6, wherein the angiogenic disease is a corneal disease, hypoxia, infection, diabetic retinopathy, retrolental fibroplasia, trachoma, neovascular glaucoma, rubeosis, or macular degeneration. 10. The method of claim 6, wherein the angiogenic disease is associated with an eye injury or laser surgery. 11. The method of claim 1, wherein the angiogenic disease is an angiogenic disease of the skin. 12. The method of claim 11, wherein the angiogenic disease is psoriasis, scleroderma, neovasculanzation as a consequence of infection, cat scratch disease, bacterial ulceration, lupus erythematosus, telangiectasia, or hypertrophic scars. 13. The method of claim 1, wherein the angiogenic disease is an angiogenic disease of the joints. 14. The method of claim 13, wherein the angiogenic disease is arthritis, rheumatoid arthritis, hemophiliac joints, lupus erythematosus, immune-inflammation, or non-immune inflammation. 15. The method of claim 1, wherein the angiogenic disease is an angiogenic disease of the gastrointestinal tract. 16. The method of claim 15, wherein the angiogenic disease is angioectasia, telangiectasia, intestinal adhesions, Crohn's disease, Oster-Webber Syndrome, or peptic ulcer. 17. The method of claim 1, wherein the angiogenic disease is an angiogenic disease associated with a fracture or would healing. 18. The method of claim 17, wherein the angiogenic disease is associated with excessive wound repair, wound granularization, or an ischemic limb. 19. The method of claim 1, further comprising administering an antiangiogenic agent to the cells in conjunction with N-.beta.2GP1. 20. The method of claim 19, wherein the antiangiogenic agent is angiostatin, endostatin, trastuzumab, TGF-.beta., thrombospondin, IL-1, IFN-.gamma., IFN-.alpha., tissue inhibitor of metalloproteinase-1 (TIMP-1), platelet factor 4 (PF4), protamine, retinoic acid, AGM-1470, fumagillin, tyrosine kinase inhibitor, an inhibitor of epidermal-derived growth factor, an inhibitor of fibroblast-derived growth factor, an inhibitor of platelet derived growth factor, an MMP (matrix metalloprotease) inhibitor, an integrin blocker, interleukin-12, pentosan polysulfate, a cyclooxygenase inhibitor, fibronectin, laminin, prolactin, carboxyamidotriazole, combretastatin A-4, squalamine, 6-O-chloroacetyl-carbonyl)-fumagillol, thalidomide, troponin-1, an antibody to VEGF, or mixtures thereof. 21. The method of claim 20, wherein the antiangiogenic agent is angiostatin, endostatin, trastuzumab, thrombospondin, IFN-.alpha., TIMP-1, PF4, fumagillin, or mixtures thereof. 22. The method of claim 1, wherein the subject is human.

Details for Patent 7,642,234

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Genentech, Inc.	HERCEPTIN	trastuzumab	For Injection	103792	09/25/1998		2039-03-29
Genentech, Inc.	HERCEPTIN	trastuzumab	For Injection	103792	02/10/2017		2039-03-29
Genentech, Inc.	HERCEPTIN HYLECTA	trastuzumab and hyaluronidase-oysk	Injection	761106	02/28/2019		2039-03-29